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Background: This retrospective analysis explored prognostic factors associated with a benign multiple sclerosis
(BMS) disease course at baseline and over the 4-year follow-up.
Methods: Patients from the centralized New York State Multiple Sclerosis Consortium registry were classified as having
BMS according to 3 different criteria centered on disease duration and disability. Additional analyses explored prognostic
factors associated with BMS using the most conservative disability criteria (Expanded Disability Status Scale ≤2
and disease duration ≥10 years).
Results: Among 6258 patients who fulfilled eligibility criteria, 19.8 % to 33.3 % were characterized as having BMS,
at baseline depending on classification criteria used. Positive prognostic factors for BMS at baseline included female sex
(p < 0.0001) and younger age at onset (p < 0.0001); negative prognostic factors included progressive-onset type of MS
and African-American race. Of the 1237 BMS patients (per most conservative criteria), 742 were followed for a median
of 4 years to explore effect of disease-modifying treatment (DMT) on benign status. DMT (p = 0.009) and longer disease
duration (p = 0.007) were the only significant positive predictors of maintaining BMS at follow-up. The protective effect
was stronger for patients taking DMT at both enrollment and follow-up (OR = 0.71; p = 0.006).
Conclusions: There is a need for development of more reliable prognostic indicators of BMS. Use of DMT was
significantly associated with maintaining a benign disease state.
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Multiple sclerosis (MS) is an immune-mediated neurode-
generative disorder of the central nervous system with a
lifetime risk of 1 in 400 in Caucasians in industrialized so-
ciety [1]. The disease course is highly heterogeneous and
includes a subgroup of patients with benign MS (BMS)
who demonstrate little disease progression and minimal
disability, even decades after clinical onset [2–5]. However,* Correspondence: rzivadinov@bnac.net
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multiple patient profiles are associated with this disease
course [2].
In 1996, an international survey conducted by the
National Multiple Sclerosis Society (NMSS) defined
BMS as a disease in which patients remain fully func-
tional across neurologic systems 15 years after disease
onset [6, 7]. Unfortunately, the term “fully functional”
was not clearly defined, resulting in considerable varia-
tions in the estimated frequency of BMS [8–10].
Benign MS is a retrospective diagnosis that can only be
made 10 years or more after disease onset. Despite con-
sensus recommendations for immediate treatment follow-
ing diagnosis, there is still a difference of opinion amongle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Zivadinov et al. BMC Neurology  (2016) 16:102 Page 2 of 10physicians regarding this issue because of the paucity of
efficacy data with disease modifying therapies (DMTs) in
patients with BMS [11–15].
The New York State MS Consortium (NYSMSC) has as-
sembled a centralized registry of demographic and clinical
information from more than 7000 patients with clinically
definite MS from across New York State (NYS), providing
a robust dataset to study the frequency and characteris-
tics of BMS. [16, 17] This study aimed to (a) retro-
spectively estimate the prevalence of BMS based on the
NYSMSC registry using the 3 most commonly used
BMS criteria [2, 3, 18]; (b) evaluate prognostic factors
associated with BMS; (c) investigate the course of BMS
prospectively over time [2, 8, 19]; and (d) explore
whether DMT use correlated with maintaining a be-




This was a retrospective cohort study characterized by
demographic, clinical, and treatment information available
from the NYSMSC centralized registry. The NYSMSC is a
regional affinity group of 18 MS centers throughout NYS
established to promote MS research and enhance patient
care [16, 20]. This study consisted of 2 parts: a cross-
sectional comparison of patients at the time of enrollment
in the registry (i.e. baseline evaluation) and the assessment
of patients with follow-up data. Patient enrollment in the
NYSMSC registry began on February 14, 1996. This date
was also the start of study enrollment. All patients with a
clinically definite MS diagnosis (CDMS) according to the
Poser criteria [21] enrolled in the NYMSC registry from
the start of the registry until December 31, 2002, were
included in the study cohort. While this later date repre-
sented the final enrollment date for inclusion in the co-
hort (i.e. December 31, 2002), a follow-up cut-off date of
October 1, 2004, was imposed for patient follow-up data.
This follow-up cut-off date was chosen to provide similar
diagnosis criteria (CDMS), at least 1 year of follow-up for
the most recently enrolled patients, and because it repre-
sented approximately 10 years since the first DMT ap-
proved for treatment of MS became available. A complete
baseline evaluation at NYSMSC enrollment, including
completion of the demographic and clinical sections of
the NYSMSC standardized data collection instrument,
was also required for study inclusion.
The standardized data collection instrument consists
of 2 sections: Section 1 contains demographic data and
self-report assessments that are completed by patients
during their regularly scheduled neurologic appoint-
ment; Section 2, completed by the examining neurologist
and/or nurse practitioner certified in Expanded Disabil-
ity Status Scale (EDSS) performance, includes signs andsymptoms at onset, relapse history, MS type, EDSS
score, and use of DMTs. All clinical, demographic, and
treatment data from enrollment and yearly (±6 months)
follow-up visits from all participating NYSMSC sites are
maintained at a centralized data management center
(UDSMR) [16, 17].
Patients were defined as receiving DMT, if they received
any of the following Food and Drug Administration
(FDA)-approved treatments and/or investigational DMTs:
FDA-approved DMTs—interferon beta-1a/b (IFN-β1a/b;
Avonex®, Rebif®, Betaseron®), glatiramer acetate (Copax-
one®), mitoxantrone (Novantrone®), and natalizumab
(Tysabri®); investigational DMTs (taken by ~1 % of
patients)—cyclophosphamide, intravenous immunoglobu-
lin, oral myelin, linomide, and azathioprine. All patients
receiving treatments that were not DMTs (e.g. symptom-
atic medications) were included in the not-treated
group for the various time points unless they also re-
ceived a DMT.
The study was approved by the relevant Institutional Re-
view Boards (IRBs) of the participating centers and written
informed consent was obtained by all study participants
prior to enrollment in the NYSMSC registry. The IRB
renewals were obtained annually on an ongoing basis
throughout the study. The permission was obtained for
using the NYSMSC database by the NYSMSC Scientific
Committee, which approved the study protocol.
Patient classification
Patients were retrospectively classified as having BMS or
non-BMS at baseline (i.e. NYSMSC enrollment) according
to the 3 most commonly used benign criteria: EDSS ≤2
and disease duration (DD) ≥10 years (Criterion I), EDSS
≤3 and DD ≥15 years (Criterion II), and EDSS ≤3 and DD
≥10 years (Criterion III) (Table 1) [2, 3, 18]. Disease
duration was defined as time from first symptom onset.
Prevalence of BMS at enrollment according to these 3
classifications was evaluated. Additional baseline and
follow-up analyses were carried out for the first benign
classification criteria (EDSS ≤2 and DD ≥10 years) be-
cause this classification was the most conservative with
respect to EDSS (referred to herein as Criterion I).
Within the context of this classification, patients were
placed into 1 of 2 categories: BMS (i.e. EDSS ≤2 and
DD <10 years) and non-BMS (i.e. EDSS ≤2 and DD <10;
years or EDSS >2 regardless of DD). For this latter cat-
egory, the worsening to EDSS >2 could have occurred at
any time during the disease course.
Statistical methods
All statistical analyses were performed using Statistical
Package for Social Sciences (SPSS Incorporated, Chicago,
IL, version 22.0). The association between clinical and
demographic variables for Criterion I benign, vs. non-
Table 1 Baseline demographic and clinical characteristics of patients with benign MS based on 3 classification criteria
Variable EDSS ≤2, DD ≥10a
(Criterion I)
EDSS ≤3, DD ≥15
(Criterion II)
EDSS ≤3, DD ≥10
(Criterion III)
Patients, n (%)b 1237 (19.8) 1253 (20.0) 2081 (33.3)














Family history,% 19.5 20.6 20.2
Age at onset, y, mean (SD) 30.2 (8.5) 29.3 (8.6) 30.8 (8.9)
Age at baseline, y, mean (SD) 47.8 (9) 51.9 (9) 49.3 (9.5)
EDSS, mean (SD) 1.4 (0.6) 2.1 (0.8) 2.0 (0.8)
EDSS, median (range) 1.5 (0–2.0) 2.0 (0–3.0) 2.0 (0–3.0)


















On DMT at enrollment, n (%)c 505 (40.8) 481 (38.4) 848 (40.7)













































DD disease duration (years from symptom onset to enrollment)
Abbreviations: DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, MS multiple sclerosis
aMost conservative definition
bOut of n = 6258 total cohort patients
cWere being treated with disease modifying therapy (DMT) at time of enrollment in the NYSMSC registry
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or Mann–Whitney u test, as appropriate.
Odds ratios and 95 % confidence intervals for predictors
of benign vs. non-BMS status adjusted for other predictors
at baseline were calculated using binary logistic regression
(LR). For these comparisons, non-BMS patients were lim-
ited to those with ≥10 years DD so as to make the two
groups similar with regard to minimum disease duration.
Cox regression models were used to explore the effect of
DMT use from enrollment through follow-up on benign
status over time while simultaneously adjusting for signifi-
cant baseline predictors of benign status in a subset of
Criterion I benign patients with follow-up data (n = 742).
Hazard ratios (HRs) and 95 % confidence intervals were
calculated from final Cox models. Backward stepwise mod-
eling was used for both LR and Cox regression, with entry
criteria set at p < 1.00 and removal criteria at p < 0.05.
Additional details regarding regression models are provided
in the footnotes of Table 3.All models were initially run with a full set of vari-
ables identified as predictors during univariate analyses,
with one exception. Because age-related variables were
highly correlated, some were eliminated from the model
to ensure that final fitted models met the underlying
assumptions of multicollinearity and Homer-Lemshow
goodness-of-fit criteria (LR). Detailed information regard-
ing variables included in the models are provided in the
footnotes for Table 3 and Fig. 1.
Data regarding DMTs taken by individual Criterion I pa-
tients included type of DMT taken at time of enrollment
and follow-up. Data regarding specific duration of DMT
use were not available. Therefore, 2 analyses were con-
ducted. In the first, DMT use was classified as Ever (n =
633) or Never (n = 109) used as of the end of follow-up.
For the second analysis, 4 categories were established
using all DMT data as of follow-up: (1) Never used DMT
(n = 109), (2) Was using DMT at time of enrollment but
not at follow-up (n = 83), (3) Used DMT at time of follow-
Fig. 1 Cox regression survival curves. Probability of remaining benign for n = 742 Criterion I benign MS patients for (a) 2-category definition of DMT
use: Ever (n = 633) vs Never (n = 109; p = 0.009) and (b) 4-category definition of DMT use: Never Used (n = 109, comparison group); at enrollment only
(n = 83, not significant); at follow-up only (n = 258, p= 0.038); at both enrollment and follow-up (n = 292, p= 0.006). Abbreviations: DMT, disease-modifying
therapy. Data from New York State Multiple Sclerosis Consortium
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on DMT at enrollment and also at follow-up (n = 292).
For this second analysis, the Never used DMT group
served as the reference category for the other 3 groups.
Forty-two benign patients from the Buffalo, NY, site who
were not on treatment at enrollment or follow-up had a
history of IFN-β1a use before its approval in 1996 as a
result of participation in the IFN-β1a phase 3 trial.
These patients (n = 42) were excluded from the Coxmodel analyses exploring the effect of DMTs on benign
status. Four additional patients were excluded from
Cox model analyses because of missing data on DMT
use at enrollment.
Results
Demographic and clinical characteristics at baseline
Of the 7158 patients enrolled in the NYSMSC registry,
6258 patients fulfilled the inclusion criteria and were
Zivadinov et al. BMC Neurology  (2016) 16:102 Page 5 of 10included in the study (Additional file 1: Figure S1). The
majority (61.9 %) of patients in the study cohort had
relapsing-remitting (RRMS), while approximately one quar-
ter of patients (26.5 %) had secondary-progressive MS
(SPMS). Only 8.0 % of patients had primary-progressive
MS (PPMS), and <4 % had progressive-relapsing (PR) MS
(Additional file 1: Figure S1). Disease course was deter-
mined per NMSS recommended criteria available at the
time of study enrollment [6].
At baseline, 19.8 % (n = 1237) of patients in the total
study cohort were classified as having BMS according to
the most conservative classification criteria (Criterion I;
Table 1). Similarly, 20 % (n = 1253) of patients were classi-
fied as having BMS using Criterion II. In contrast, when
using the least conservative classification (Criterion III),
33.3 % (n = 2081) of patients were classified as having
BMS (Table 1).
The descriptive data in Table 1 suggest that some demo-
graphic and clinical characteristics differed according to
criteria, especially for Criterion I vs Criterion II. Certain
differences were expected based on criteria definitions
(e.g. lower mean EDSS for benign patients in the Criterion
I group vs those in Criterion II and III groups, and shorter
mean disease durations for BMS in the Criterion I
[17 years] and III groups [17.9 years] compared with those
in the Criterion II group [22 years]). Disease course also
varied for patients defined as having BMS based on Criter-
ion I vs Criterion II and III (Table 1). The percentage of
patients with RRMS was higher among Criterion I BMS
patients (95.6 %) than among Criterion II (86.4 %) and
Criterion III (88.4 %) BMS patients.
In the total cohort of MS patients (n = 6258), use of
the most conservative classification criteria (Criterion I)
resulted in 19.8 % of patients classified as benign at
baseline. 80.2 % of patients were classified as having
non-BMS (Table 2). In univariate analyses comparing
Criterion I BMS patients with non-BMS patients at base-
line, significant differences between patients with BMS,
vs non-BMS patients were seen with respect to nearly all
baseline demographic and clinical characteristics assessed
with the exception of family history of MS (Table 2). Less
than 1 % of the total cohort who met Criteria I criteria for
benign status had progressive disease (SP, PP or SP).
Removing these patients from the analysis made no differ-
ence in statistical significance of results, nor did considering
them non-BMS due to their status as progressive patients
(Table 2). Positive predictors of conservative-criteria BMS
at baseline included female sex (p < 0.0001) and younger
age at onset (p < 0.0001). Patients with progressive-onset
type of MS and those of African-American race were
less likely to have BMS at baseline (Table 2). Of the 382
African-American patients included in the study co-
hort, 11.8 % were classified as having Criterion I BMS.
In LR models, comparing benign (EDSS ≤2) with non-BMS patients with DD ≥10 years for both groups, find-
ings were similar to those of univariate 2-group com-
parisons, except that BMS patients were more likely to
have a later age at onset than non-BMS patients after
adjusting for other variables in the model.
Characteristics of criterion I benign patients at follow-up
Follow-up data were available for significantly fewer pa-
tients (n = 3583, 57.3 %) compared with the original co-
hort (median cohort follow-up 3 years, range 1–8 years).
Of the 1237 (19.8 %) patients originally classified as having
BMS at baseline per Criterion I, 788 (63.7 %) had follow-
up data available (median follow-up 4 years, range 1–8
years). Of these patients, 64.8 % (n = 511) continued to
present with BMS at follow-up, whereas the remaining
35.2 % of patients (n = 277) had progressed to non-BMS.
Factors associated with loss to follow-up
Logistic regression analyses also were used to evaluate fac-
tors predicting loss to follow-up. The full model tested
included sex, race, disease course, DD, age at disease on-
set, and Criterion I classification (i.e. benign vs non-
BMS). Variables that predicted higher loss to follow-up
included having SPMS (p < 0.0001) or PPMS (p < 0.05)
course; longer DD (p < 0.05); and being in the non-BMS
group (p < 0.0001).
DMTs in benign patients by criterion I cohort at baseline
and follow-up
Most patients on DMT at enrollment and/or follow-up
were on 1 of 3 DMTs: (1) IFN-β1a (Avonex)—enrollment
only, n = 33; follow-up only, n = 157; (2) IFN-β1b (Betaser-
on)—enrollment only, n = 27; follow-up only, n = 37; or
(3) glatiramer acetate (Copaxone)—enrollment only, n = 9;
follow-up only, n = 53. Eight patients were taking metho-
trexate alone at enrollment, and 1 at follow-up. One
patient was taking subcutaneous IFN-β1a (Rebif) at enroll-
ment, and 6 at follow-up. Other DMTs taken by ≤1.2 % of
patients at enrollment or follow-up were cyclophospha-
mide, mitoxantrone (Novantrone), intravenous immuno-
globulin, oral myelin, linomide, and azathioprine.
Two-hundred ninety-two patients were on DMT at both
enrollment and follow-up, including 173 on IFN-β1a
(Avonex), 32 on glatiramer acetate (Copaxone), 44 on
IFN-β1b (Betaseron), and 1 on IFN-β1a (Rebif). The re-
mainder of patients on DMT at both time points (n = 42)
changed DMT between enrollment and follow-up. One
hundred nine patients (14.7 %) had no history of DMT use
at enrollment and did not use DMT during the study.
Effect of DMT on continued benign status in criterion I
cohort
Cox models were used to simultaneously evaluate sig-
nificant baseline predictors of benign status and DMT
Table 2 Baseline demographic and clinical characteristics of MS patients with benign MS according to classification Criterion Ia
(EDSS ≤2 and DD ≥10 years) vs. non-benign MS patients
Variable BMS (EDSS ≤2, DD ≥10)a Non-BMS p-value*
All Patients, n (%)b 1237 (19.8) 5021 (80.2) <0.0001












Family history, n, (%) 241 (19.5) 976 (19.4) NS
Age at onset, y, mean (SD) 30.2 (8.5) 32.2 (9.7) <0.0001
Age at baseline, y, mean (SD) 47.8 (9.0) 51.8 (10.5) <0.0001
EDSS, mean (SD) 1.4 (0.6) 4.4 (1.6) <0.0001
EDSS, median (range) 1.5 (0–2.0) 5.0 (0–9.5) <0.0001















DMT at enrollment, n (%)e 505 (40.8) 2182 (81.2) p < 0.0001






































Abbreviations: MS multiple sclerosis, BMS benign MS, DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, IM intramuscular, NS not significant,
SC subcutaneous, SD standard deviation
*Between-group comparisons were performed using chi-square, t-tests, or Mann–Whitney U tests as appropriate
aMost conservative classification criteria definition
bDenominators: Benign MS (n = 1237); Other MS (n = 5021)
cDD, disease duration (years from symptom onset to enrollment)
dAt time of baseline enrollment, only 53 progressive patients (SP, PR, and PP) out of the entire cohort of 6,258 (<1 %) met classification Criterion Ia (EDSS ≤2 and
DD ≥10 years) for benign MS. Removing these patients from the analysis made no difference in statistical significance of results, nor did considering them
non-benign due to their status as progressive patients
eDMT at enrollment, n = 2687 (42.9 %) of total cohort (n = 6258) (benign MS on DMT, n = 505; other MS on DMT n = 2182)
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significant predictors of remaining benign at follow-up in
the final fitted model were Ever used DMT (p = 0.009)
and longer DD (p = 0.007), both of which were protective
(Table 3, Fig. 1a). Longer DD and DMT use were also the
only variables remaining in the final model for the analysis
in which DMTs were grouped into 4 categories. In this
latter analysis, likelihood of remaining benign at follow-up
for those who took DMT at time of enrollment but
stopped taking DMT before follow-up was not signifi-
cantly different from Never used DMT. However, a protect-
ive effect was seen for those patients taking DMTat follow-
up (HR = 0.80; p = 0.037). Furthermore, the protective effect
was stronger and more significant for patients taking DMTat both enrollment and follow-up (HR = 0.71; p = 0.006)
(Table 3 and Fig. 1b).
Discussion
Although various definitions for the classification have
been proposed, BMS is generally characterized by the lack
of disease progression and minimal disability 10 years or
more after disease onset [2, 19, 22]. The considerable
variation in the estimated frequency of BMS has the po-
tential to influence treatment decisions because, historic-
ally, some clinicians were reluctant to prescribe DMTs for
patients with little evidence of physical disability [10]. Our
own data supports this observation. At time of enrollment
into the study cohort, only 40.8 % of benign MS patients
Table 3 DMT use as a predictor of continued benign status at
follow-up in those who were benign at enrollment (n = 742)a,b,c,d
(A) DMT use Ever(n = 633)/Never (n = 109)e,f
HR (95 % CI) p value
DMT use at enrollment and/or follow-up





(B) DMT use 4-category Cox modele,f
HR (95 % CI) p value
DMT use at enrollment only (n = 83)
DMT use at follow-up only (n = 258)
DMT use at both enrollment and
follow-up (n = 292)









CI confidence interval, DMT disease-modifying therapy, HR hazard ratio
MS multiple sclerosis
aCox regression analyses
bThe following variables were entered into the full Cox models comparing late
benign with benign patients: sex, disease course, race, treatment status, age at
onset and disease duration
cContinuous variables: age at onset (years), disease duration (years since
symptom onset)
dCategorical variables: sex: female compared with male; disease course:
secondary-progressive, progressive-relapsing, primary-progressive, compared
with relapsing-remitting MS; race: African-American, Other, compared with
Caucasian; treatment categories: See footnote f, below
eForty-six of 788 Criteria I baseline benign follow-up patients were excluded
from Cox regression analyses, leaving a total of N = 742 patients; N = 42
patients who were not on treatment at enrollment or follow-up but had a
history of IFN-β1a use prior to its approval in 1996 as a result of participation
in the IFN-β1a phase 3 trial, and N = 4 patients who were missing DMT data
Never Users: n = 109 patients had no history of DMT use at enrollment and did
not use DMT at any time during the study. This group served as the reference
category for DMT use in the Ever/Never and 4-category Cox models. DMTs used
included interferon beta-1a/b (Avonex®, Rebif®, Betaseron®), glatiramer acetate
(Copaxone®), azathioprine, cyclophosphamide, intravenous immunoglobulin,
methotrexate, linomide, myelin therapy; mitoxantrone, and natalizumab
(1 patient on clinical trial)
fThere was no difference in likelihood of remaining benign vs converting to
late non-benign during follow-up according to sex, disease course, race, or
age at onset after adjusting for significant predictors included in the
final model
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(more than twice the rate of BMS patients, p < 0.0001)
were on DMTs (Table 2). Current recommendations
propose DMTs for patients with MS from date of diagno-
sis without waiting to determine whether they meet the
criteria for benign disease [11, 13, 23].
This large study, which included 6258 patients enrolled
in the NYSMSC registry, evaluated the frequency and char-
acteristics of BMS in a prevalence cohort including patients
from 18 centers across NYS accrued over a 6-year time
period. Patients receiving investigational DMTs were in-
cluded in the study to maintain the completeness of the
dataset. The large sample size of this prevalence cohort
allowed us to identify the prevalence of BMS and com-
pare demographic and clinical characteristics of BMS
according to the 3 most commonly used classification
criteria [2, 3, 18], as well as to identify prognostic
factors associated with the disease course of BMS.
Based on the classification criteria used, the overallpercentage of patients with BMS at enrollment was
19.8 % to 33.3 % at baseline, which is in accordance
with previous studies [2, 10].
Our data suggest that patients with SPMS, PRMS, and
PPMS disease course are less likely to remain benign
over time than those with RRMS disease course, which
is consistent with results previously reported in the lit-
erature [10, 18, 24]. Both baseline and follow-up data
support the recommendations of others that the term
“benign” MS should be reserved for patients with RRMS
disease course [2, 3, 7, 8, 18, 22]. In cross-sectional base-
line analyses, several demographic, clinical, and treat-
ment factors increased the likelihood of being classified
as benign. However, in exploratory Cox model analyses
of benign patients over time, use of DMT and longer
DD were the only significant prognostic factors for con-
tinued BMS. The data surrounding the use of DMTs
suggest that there are benefits of early preventive treat-
ment even in the absence of signs of physical disability.
However, while follow-up analyses were limited to pa-
tients with baseline EDSS ≤2.0 after 10 or more years of
disease duration, correlation between EDSS score and
DMT use was not directly studied herein. Nevertheless,
these novel findings support the consensus statements
issued by the NMSS in 2008 and the Consortium of
Multiple sclerosis Centers (CMSC) in 2014 regarding
early initiation of DMTs upon definitive MS diagnosis
for patients and continuing treatment in those who are
appropriate candidates for these agents [11, 12]. Use of
DMTs early in the MS disease course has been sup-
ported by pharmacoeconomics studies that indicate early
vs. delayed treatment with IFN-β, in particular, may be
more cost-effective in the long term, as reduction of
relapses, hospitalizations, and indirect costs, and gains
in quality of life, and appear to outweigh the costs of
DMTs [14, 15, 25].
Our findings should be considered also in context of
the study limitations. The diagnosis of MS at baseline
and at follow-up was not based on McDonald but on
Poser criteria [21, 26, 27]. Length of follow-up included
in the follow-up analyses, was not the same for each pa-
tient but varied from 1 to 8 years. With the exception of
2 patients who were exposed to DMTs in clinical trials
during the follow-up period, study patients were primar-
ily treated with first-generation DMTs. Furthermore, this
was a historical study, and available data did not allow
us to examine every potential prognostic factor for BMS,
including MRI. For example, because data on specific
symptom at onset were not available for the cohort stud-
ied (i.e. optic neuritis, sensory symptoms, and longer
time intervals from onset to the second attack), some
factors previously shown to be prognostic of BMS were
not examined herein [10, 18, 24]. Another limitation is the
missing data on cognitive status, as EDSS used within this
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Similarly, additional factors may be prognostic for patient
loss to follow-up, and we may not have identified all pos-
sible causes of missing follow-up data. Also, while this was
an exploratory study and we evaluated factors that pre-
dicted loss to follow-up, it is still possible that bias may
have been introduced due to loss to follow-up. Our find-
ing that less than 1 % of progressive patients in the study
cohort met criteria for BMS at baseline supports the no-
tion that that progressive patients should not be classified
as benign, regardless of whether they meet EDSS and DD
criteria for benign classification.
Nevertheless, this study has several strengths, includ-
ing the large, NYS-based, centralized dataset of patients
with MS that includes almost 400 African-American pa-
tients, some of whom had BMS; a comparison of the
prevalence of BMS according to 3 different definitions of
benign status; and the availability of treatment data that
allowed us to explore the potential effect of DMT on
likelihood of continued benign status.
The results in the African-American subset of patients
in our cohort are consistent with previous findings from
our group and others that African-American patients
with MS are likely to experience more rapid progression
of disease than Caucasians [20, 28, 29]. However, while
they were less likely to be classified as benign at baseline,
African-American patients with BMS were just as likely
to remain benign over time as Caucasians after control-
ling for other significant predictors of maintaining be-
nign status. It is unlikely that this finding is the result of
differential loss to follow-up or differing follow-up times
because African-American race was not associated with
loss to follow-up, and median follow-up years for African-
Americans with BMS was not significantly different from
that of other BMS patients (4.5 vs 4.0 years).
On the basis of our historical cohort study findings
and those from various studies reported in the litera-
ture, we support the recommendation of Pittock and
others to narrow the definition of BMS to an EDSS ≤2
after a minimum of 10 years’ DD, at least until more re-
liable predictors of BMS (i.e. genetic, biologic, or im-
aging biomarkers) have been fully developed and validated
[2, 8, 22]. Many patients retrospectively classified as hav-
ing BMS may ultimately transition to a non-BMS, pro-
gressive form of MS, even using these more conservative
criteria [4, 5, 16, 19, 30].
Conclusions
Taken in context with previously reported benefits of the
early initiation of DMT for patients diagnosed with MS
[4, 9, 16, 25], our findings suggest that early initiation
and continued treatment with DMT may increase the
likelihood of maintaining BMS classification over the
course of patients’ lives, thereby ameliorating disabilityprogression, and are worth further consideration and
evaluation.
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